Daily Low-Dose Aspirin and Cancer Risk
A study published in JAMA Oncology suggests that daily low-dose aspirin may decrease cancer risk for some adults.
According to the research, Clonal Hematopoiesis of Indeterminate Potential (CHIP) at a Variant Allele Frequency (VAF) of 10% or greater is the strongest predictor of whether daily low-dose aspirin can help prevent cancer in healthy, older adults.
CHIP is the strongest predictor of whether daily low-dose aspirin could help prevent cancer in healthy, older adults.
The study was a non-prespecified secondary analysis of the randomized Aspirin in Reducing Events in the Elderly (ASPREE) trial and the ASPREE-CHIP substudy, which found no difference in cancer incidence among participants who received 100 mg of daily aspirin compared to placebo.
However, the effectiveness of daily low-dose aspirin in reducing cancer risk varied widely across the study cohort, indicating that personalized treatment approaches would be beneficial.
Author's summary: Aspirin may reduce cancer risk in some adults.
More News
- Flautist Sir James Galway to be honoured as ‘musical icon’ by Ulster University
- Micro-credentialing redefines how graduates break into new careers - IT-Online
- Asrani's first acting role was in a FTII training film directed by Ritwik Ghatak, says film scholar
- ACCC takes Microsoft to court over pricier Copilot 365 plans
- ‘Chainsaw Man’ Whips Past $100M WW; ‘One Battle After Another’ Keeps Raging – International Box Office
- Celebrity Traitors Joe Marler attacks Jonathan Ross